Christopher Heery - Feb 3, 2022 Form 4 Insider Report for Arcellx, Inc. (ACLX)

Role
Chief Medical Officer
Signature
/s/ Lance Thibault, as Attorney-in-Fact
Stock symbol
ACLX
Transactions as of
Feb 3, 2022
Transactions value $
$0
Form type
4
Date filed
2/7/2022, 04:57 PM
Next filing
Sep 30, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACLX Stock Option (right to buy) Award $0 +260K $0.00 260K Feb 3, 2022 Common Stock 260K $15.00 Direct F1
transaction ACLX Restricted Stock Unit Award $0 +67.7K $0.00 67.7K Feb 7, 2022 Common Stock 67.7K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean February 7, 2022.